(Yicai Global) April 28 -- China National Biotec today began clinical trials of its second and China’s fourth vaccine for Covid-19 after receiving approval from the National Medical Products Administration, according to The Paper.

The company’s Beijing research team developed the shot with the National Institute for Viral Disease Control and Prevention under the Chinese Center for Disease Control and Prevention.

Editor: James Boynton